Avalo Therapeutics Inc (AVTX)

$15.80 -0.91 (-5.45%)
Market Cap 292.51M
Revenue (ttm) 440,000.00
Net Income (ttm) -35.13M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin -7,984.09%
Debt to Equity Ratio 0.00
Volume 314,400
Avg Vol 460,310
Day's Range N/A - N/A
Shares Out 18.51M
Stochastic %K 10%
Beta 0.84
Analysts Strong Sell
Price Target $36.11

Company Profile

Avalo Therapeutics, Inc., a clinical stage biotechnology company, focuses on the development of therapies for the treatment of immune dysregulation in the Unites States. Its lead asset includes AVTX-009, a humanized monoclonal antibody that binds to interleukin-1ß, which is in phase 2 clinical trial to treat inflammatory diseases. The company was formerly known as Cerecor Inc. and changed its name to Avalo Therapeutics, Inc. in August 2021. Avalo Therapeutics, Inc. was incorporated in 2011 and i...

Industry: Biotechnology
Sector: Healthcare
Phone: 410 522 8707
Address:
540 Gaither Road, Suite 400, Rockville, United States
DragonAlgo
DragonAlgo Mar. 13 at 11:14 PM
🐉 $AVTX CALL — DragonAlgo® Signal Contract: AVTX CALL Expiry: 2026-06-18 | Strike: $10.00 | Type: CALL Option Plan (premium): Entry: $9.40 Stop: $6.77 TP1: $12.22 TP2: $15.98 TP3: $22.56 Active momentum environment. 🔗 https://dragonalgo.com
0 · Reply
Trapjaw
Trapjaw Mar. 13 at 4:41 PM
$AVTX
0 · Reply
DragonAlgo
DragonAlgo Mar. 13 at 7:49 AM
🐉 $AVTX PUT — DragonAlgo® Signal Contract: AVTX PUT Expiry: 2026-03-20 | Strike: $15.00 | Type: PUT Option Plan (premium): Entry: $0.60 Stop: $0.43 TP1: $0.78 TP2: $1.02 TP3: $1.44 Risk preset by model constraints. 🔗 https://dragonalgo.com
0 · Reply
DragonAlgo
DragonAlgo Mar. 12 at 7:28 PM
🐉 $AVTX CALL — DragonAlgo® Signal Contract: AVTX CALL Expiry: 2026-06-18 | Strike: $10.00 | Type: CALL Option Plan (premium): Entry: $10.25 Stop: $7.38 TP1: $13.33 TP2: $17.43 TP3: $24.60 🔗 https://dragonalgo.com
0 · Reply
DragonAlgo
DragonAlgo Mar. 12 at 1:54 AM
🐉 $AVTX CALL — DragonAlgo® Signal Contract: AVTX CALL Expiry: 2026-06-18 | Strike: $10.00 | Type: CALL Option Plan (premium): Entry: $10.55 Stop: $7.60 TP1: $13.72 TP2: $17.94 TP3: $25.32 🔗 https://dragonalgo.com
0 · Reply
Trapjaw
Trapjaw Mar. 11 at 3:10 PM
$AVTX again mass ive vol ume for this
0 · Reply
DragonAlgo
DragonAlgo Mar. 11 at 8:35 AM
🐉 $AVTX PUT — DragonAlgo® Signal Contract: AVTX PUT Expiry: 2026-03-20 | Strike: $15.00 | Type: PUT Option Plan (premium): Entry: $0.60 Stop: $0.43 TP1: $0.78 TP2: $1.02 TP3: $1.44 🔗 https://dragonalgo.com
0 · Reply
DragonAlgo
DragonAlgo Mar. 10 at 1:49 PM
🐉 $AVTX PUT — DragonAlgo® Signal Contract: AVTX PUT Expiry: 2026-04-17 | Strike: $12.50 | Type: PUT Option Plan (premium): Entry: $1.95 Stop: $1.40 TP1: $2.54 TP2: $3.31 TP3: $4.68 🔗 https://dragonalgo.com
0 · Reply
Trapjaw
Trapjaw Mar. 10 at 1:39 PM
$AVTX 140 k vol ume first 10
0 · Reply
Trapjaw
Trapjaw Mar. 5 at 3:27 PM
$AVTX huuge vol ume for 1
0 · Reply
Latest News on AVTX
Avalo Therapeutics to Participate in Upcoming Investor Conferences

Feb 24, 2026, 7:00 AM EST - 19 days ago

Avalo Therapeutics to Participate in Upcoming Investor Conferences

Avalo Therapeutics Announces Inducement Grants to New Employees Under Nasdaq Listing Rule 5635(c)(4)

Feb 18, 2026, 4:05 PM EST - 25 days ago

Avalo Therapeutics Announces Inducement Grants to New Employees Under Nasdaq Listing Rule 5635(c)(4)

Avalo Therapeutics Stock Has More Than 200% Upside? Analyst Breaks Down Bull And Bear Case

Feb 2, 2026, 2:25 PM EST - 5 weeks ago

Avalo Therapeutics Stock Has More Than 200% Upside? Analyst Breaks Down Bull And Bear Case

Avalo Therapeutics Reports Third Quarter 2025 Financial Results and Recent Business Updates

Nov 6, 2025, 7:00 AM EST - 4 months ago

Avalo Therapeutics Reports Third Quarter 2025 Financial Results and Recent Business Updates

Avalo Therapeutics Announces Completion of Enrollment in Phase 2 LOTUS Trial of AVTX-009 for the Treatment of Hidradenitis Suppurativa

Oct 29, 2025, 7:00 AM EDT - 4 months ago

Avalo Therapeutics Announces Completion of Enrollment in Phase 2 LOTUS Trial of AVTX-009 for the Treatment of Hidradenitis Suppurativa

Avalo Therapeutics Expands Leadership Team with Key Appointments in Business Development and Human Resources

Oct 1, 2025, 7:00 AM EDT - 5 months ago

Avalo Therapeutics Expands Leadership Team with Key Appointments in Business Development and Human Resources

Avalo Therapeutics Appoints Kevin R. Lind to Board of Directors

Sep 22, 2025, 7:00 AM EDT - 6 months ago

Avalo Therapeutics Appoints Kevin R. Lind to Board of Directors

Avalo Therapeutics: Speculative Buy Ahead Of AVTX-009's LOTUS Results

Aug 18, 2025, 8:30 AM EDT - 7 months ago

Avalo Therapeutics: Speculative Buy Ahead Of AVTX-009's LOTUS Results

Avalo Reports Second Quarter 2025 Financial Results and Recent Business Updates

Aug 7, 2025, 7:00 AM EDT - 7 months ago

Avalo Reports Second Quarter 2025 Financial Results and Recent Business Updates

Avalo Therapeutics Announces Appointment of Rita Jain, M.D. to Board of Directors

Jun 18, 2025, 7:00 AM EDT - 9 months ago

Avalo Therapeutics Announces Appointment of Rita Jain, M.D. to Board of Directors

Avalo Reports First Quarter 2025 Financial Results and Recent Business Updates

May 12, 2025, 7:00 AM EDT - 10 months ago

Avalo Reports First Quarter 2025 Financial Results and Recent Business Updates

Avalo Therapeutics to Participate in The Citizens Life Sciences Conference

Apr 30, 2025, 7:00 AM EDT - 11 months ago

Avalo Therapeutics to Participate in The Citizens Life Sciences Conference

Avalo Therapeutics Appoints Michael Heffernan as Chairman of the Board

Mar 26, 2025, 7:00 AM EDT - 1 year ago

Avalo Therapeutics Appoints Michael Heffernan as Chairman of the Board

Avalo Therapeutics 'Represents An Attractive Pure-Play,' Analyst Initiates Coverage With Over 300% Stock Upside

Mar 25, 2025, 3:20 PM EDT - 1 year ago

Avalo Therapeutics 'Represents An Attractive Pure-Play,' Analyst Initiates Coverage With Over 300% Stock Upside

Avalo Reports 2024 Financial Results and Recent Business Updates

Mar 20, 2025, 7:00 AM EDT - 1 year ago

Avalo Reports 2024 Financial Results and Recent Business Updates

Avalo Therapeutics to Present at Oppenheimer's 35th Annual Healthcare Life Sciences Conference

Feb 4, 2025, 8:00 AM EST - 1 year ago

Avalo Therapeutics to Present at Oppenheimer's 35th Annual Healthcare Life Sciences Conference

Avalo Therapeutics Appoints Jennifer Riley as Chief Strategy Officer

Jan 2, 2025, 7:00 AM EST - 1 year ago

Avalo Therapeutics Appoints Jennifer Riley as Chief Strategy Officer

Avalo Therapeutics Receives $69.4 Million in Proceeds from the Full Exercise of Private Placement Warrants

Nov 12, 2024, 7:00 AM EST - 1 year ago

Avalo Therapeutics Receives $69.4 Million in Proceeds from the Full Exercise of Private Placement Warrants

Avalo Therapeutics to Present at Upcoming Investor Conferences

Nov 11, 2024, 7:00 AM EST - 1 year ago

Avalo Therapeutics to Present at Upcoming Investor Conferences

Avalo Announces First Patient Dosed in Phase 2 LOTUS Trial of AVTX-009 for the Treatment of Hidradenitis Suppurativa

Oct 8, 2024, 7:00 AM EDT - 1 year ago

Avalo Announces First Patient Dosed in Phase 2 LOTUS Trial of AVTX-009 for the Treatment of Hidradenitis Suppurativa

Avalo Therapeutics Announces Appointment of Dr. Mittie Doyle as Chief Medical Officer

Jul 16, 2024, 7:00 AM EDT - 1 year ago

Avalo Therapeutics Announces Appointment of Dr. Mittie Doyle as Chief Medical Officer

Avalo Therapeutics Announces Active IND for AVTX-009, an anti-IL-1β mAb, to Treat Hidradenitis Suppurativa

Jul 9, 2024, 7:00 AM EDT - 1 year ago

Avalo Therapeutics Announces Active IND for AVTX-009, an anti-IL-1β mAb, to Treat Hidradenitis Suppurativa

Avalo Therapeutics Announces Appointment of Paul Varki as Chief Legal Officer

Jun 24, 2024, 4:01 PM EDT - 1 year ago

Avalo Therapeutics Announces Appointment of Paul Varki as Chief Legal Officer

Avalo to Present at the Oppenheimer Novel Targets in Immunology Summit

Jun 17, 2024, 7:30 AM EDT - 1 year ago

Avalo to Present at the Oppenheimer Novel Targets in Immunology Summit

Avalo Reports First Quarter 2024 Financial Results and Provides Business Updates

May 13, 2024, 7:30 AM EDT - 1 year ago

Avalo Reports First Quarter 2024 Financial Results and Provides Business Updates

Avalo Therapeutics Appoints Biotech Leaders to Board of Directors

Apr 2, 2024, 7:00 AM EDT - 2 years ago

Avalo Therapeutics Appoints Biotech Leaders to Board of Directors

Avalo Therapeutics (AVTX) stock slips after earnings: buy the dip?

Apr 1, 2024, 6:02 AM EDT - 2 years ago

Avalo Therapeutics (AVTX) stock slips after earnings: buy the dip?

Avalo Reports 2023 Financial Results and Provides Business Updates

Mar 29, 2024, 4:01 PM EDT - 2 years ago

Avalo Reports 2023 Financial Results and Provides Business Updates

Avalo Acquires Anti-IL-1β mAb and Announces Private Placement Financing of up to $185 Million

Mar 27, 2024, 4:01 PM EDT - 2 years ago

Avalo Acquires Anti-IL-1β mAb and Announces Private Placement Financing of up to $185 Million

Avalo Therapeutics Announces 1-for-240 Reverse Stock Split

Dec 27, 2023, 7:00 AM EST - 2 years ago

Avalo Therapeutics Announces 1-for-240 Reverse Stock Split

Avalo Encourages Stockholders to Vote FOR the Reverse Stock Split

Dec 7, 2023, 7:00 AM EST - 2 years ago

Avalo Encourages Stockholders to Vote FOR the Reverse Stock Split

Avalo Reports Third Quarter 2023 Financial Results and Provides Business Updates

Nov 9, 2023, 7:00 AM EST - 2 years ago

Avalo Reports Third Quarter 2023 Financial Results and Provides Business Updates

Avalo Completes Divestiture of AVTX-800 Series

Oct 31, 2023, 7:00 AM EDT - 2 years ago

Avalo Completes Divestiture of AVTX-800 Series

Top trending biotech stocks: ANVS, MTNB, AVTX, TPST

Oct 12, 2023, 11:26 AM EDT - 2 years ago

Top trending biotech stocks: ANVS, MTNB, AVTX, TPST

ANVS MTNB TPST

Avalo Therapeutics Successfully Eliminates $35 Million Debt Paving the Way for Future Growth and Innovation

Sep 26, 2023, 7:00 AM EDT - 2 years ago

Avalo Therapeutics Successfully Eliminates $35 Million Debt Paving the Way for Future Growth and Innovation

As AVTX stock price soars, Avalo Therapeutics bankruptcy remains

Sep 26, 2023, 2:10 AM EDT - 2 years ago

As AVTX stock price soars, Avalo Therapeutics bankruptcy remains

Avalo Enters into Agreement to Divest AVTX-800 Series

Sep 12, 2023, 7:00 AM EDT - 2 years ago

Avalo Enters into Agreement to Divest AVTX-800 Series

Avalo to Present at the H.C. Wainwright 25th Annual Global Investment Conference

Sep 6, 2023, 7:00 AM EDT - 2 years ago

Avalo to Present at the H.C. Wainwright 25th Annual Global Investment Conference

Avalo Reports Second Quarter 2023 Financial Results and Provides Business Updates

Aug 3, 2023, 7:00 AM EDT - 2 years ago

Avalo Reports Second Quarter 2023 Financial Results and Provides Business Updates

Avalo to Participate in SVB Securities Therapeutics Forum

Jul 6, 2023, 4:01 PM EDT - 2 years ago

Avalo to Participate in SVB Securities Therapeutics Forum

Avalo Announces Topline Data from Phase 2 PEAK Trial for AVTX-002 (quisovalimab) in Patients with Non-Eosinophilic Asthma

Jun 26, 2023, 7:00 AM EDT - 2 years ago

Avalo Announces Topline Data from Phase 2 PEAK Trial for AVTX-002 (quisovalimab) in Patients with Non-Eosinophilic Asthma

Avalo to Present at the Jefferies Healthcare Conference

Jun 1, 2023, 7:00 AM EDT - 3 years ago

Avalo to Present at the Jefferies Healthcare Conference

Avalo Announces Appointment of Michael Croft, Ph.D. and Jeff Edelson, M.D.

May 22, 2023, 7:00 AM EDT - 3 years ago

Avalo Announces Appointment of Michael Croft, Ph.D. and Jeff Edelson, M.D.

Avalo to Present at ATS 2023 Respiratory Innovation Summit

May 15, 2023, 7:00 AM EDT - 3 years ago

Avalo to Present at ATS 2023 Respiratory Innovation Summit

Avalo to Present at the 2023 RBC Capital Markets Global Healthcare Conference

May 10, 2023, 7:00 AM EDT - 3 years ago

Avalo to Present at the 2023 RBC Capital Markets Global Healthcare Conference

Avalo Reports First Quarter 2023 Financial Results and Provides Business Updates

May 4, 2023, 4:01 PM EDT - 3 years ago

Avalo Reports First Quarter 2023 Financial Results and Provides Business Updates

Avalo Reports 2022 Financial Results and Provides Business Updates

Mar 29, 2023, 7:30 AM EDT - 3 years ago

Avalo Reports 2022 Financial Results and Provides Business Updates

Avalo to Present at Oppenheimer's 33rd Annual Healthcare Conference

Mar 7, 2023, 7:00 AM EST - 3 years ago

Avalo to Present at Oppenheimer's 33rd Annual Healthcare Conference

Avalo Therapeutics, Inc. Announces Pricing of $15 Million Public Offering of Common Stock and Warrants

Feb 2, 2023, 9:54 PM EST - 3 years ago

Avalo Therapeutics, Inc. Announces Pricing of $15 Million Public Offering of Common Stock and Warrants

Avalo Therapeutics, Inc. Announces Proposed Public Offering of Common Stock and Warrants

Feb 2, 2023, 4:01 PM EST - 3 years ago

Avalo Therapeutics, Inc. Announces Proposed Public Offering of Common Stock and Warrants

DragonAlgo
DragonAlgo Mar. 13 at 11:14 PM
🐉 $AVTX CALL — DragonAlgo® Signal Contract: AVTX CALL Expiry: 2026-06-18 | Strike: $10.00 | Type: CALL Option Plan (premium): Entry: $9.40 Stop: $6.77 TP1: $12.22 TP2: $15.98 TP3: $22.56 Active momentum environment. 🔗 https://dragonalgo.com
0 · Reply
Trapjaw
Trapjaw Mar. 13 at 4:41 PM
$AVTX
0 · Reply
DragonAlgo
DragonAlgo Mar. 13 at 7:49 AM
🐉 $AVTX PUT — DragonAlgo® Signal Contract: AVTX PUT Expiry: 2026-03-20 | Strike: $15.00 | Type: PUT Option Plan (premium): Entry: $0.60 Stop: $0.43 TP1: $0.78 TP2: $1.02 TP3: $1.44 Risk preset by model constraints. 🔗 https://dragonalgo.com
0 · Reply
DragonAlgo
DragonAlgo Mar. 12 at 7:28 PM
🐉 $AVTX CALL — DragonAlgo® Signal Contract: AVTX CALL Expiry: 2026-06-18 | Strike: $10.00 | Type: CALL Option Plan (premium): Entry: $10.25 Stop: $7.38 TP1: $13.33 TP2: $17.43 TP3: $24.60 🔗 https://dragonalgo.com
0 · Reply
DragonAlgo
DragonAlgo Mar. 12 at 1:54 AM
🐉 $AVTX CALL — DragonAlgo® Signal Contract: AVTX CALL Expiry: 2026-06-18 | Strike: $10.00 | Type: CALL Option Plan (premium): Entry: $10.55 Stop: $7.60 TP1: $13.72 TP2: $17.94 TP3: $25.32 🔗 https://dragonalgo.com
0 · Reply
Trapjaw
Trapjaw Mar. 11 at 3:10 PM
$AVTX again mass ive vol ume for this
0 · Reply
DragonAlgo
DragonAlgo Mar. 11 at 8:35 AM
🐉 $AVTX PUT — DragonAlgo® Signal Contract: AVTX PUT Expiry: 2026-03-20 | Strike: $15.00 | Type: PUT Option Plan (premium): Entry: $0.60 Stop: $0.43 TP1: $0.78 TP2: $1.02 TP3: $1.44 🔗 https://dragonalgo.com
0 · Reply
DragonAlgo
DragonAlgo Mar. 10 at 1:49 PM
🐉 $AVTX PUT — DragonAlgo® Signal Contract: AVTX PUT Expiry: 2026-04-17 | Strike: $12.50 | Type: PUT Option Plan (premium): Entry: $1.95 Stop: $1.40 TP1: $2.54 TP2: $3.31 TP3: $4.68 🔗 https://dragonalgo.com
0 · Reply
Trapjaw
Trapjaw Mar. 10 at 1:39 PM
$AVTX 140 k vol ume first 10
0 · Reply
Trapjaw
Trapjaw Mar. 5 at 3:27 PM
$AVTX huuge vol ume for 1
0 · Reply
DragonAlgo
DragonAlgo Mar. 5 at 12:21 AM
🐉 $AVTX CALL — DragonAlgo® Signal Contract: AVTX CALL Expiry: 2026-06-18 | Strike: $10.00 | Type: CALL Option Plan (premium): Entry: $11.70 Stop: $8.42 TP1: $15.21 TP2: $19.89 TP3: $28.08 Momentum tape remains active. 🔗 https://dragonalgo.com
0 · Reply
OfficialStocktwitsUser
OfficialStocktwitsUser Mar. 4 at 4:56 PM
$AVTX RSI: 71.93, MACD: 0.6635 Vol: 1.70, MA20: 15.59, MA50: 16.24 ⚪ HOLD - Sideways 👉 https://quantumstockalerts.com Disclaimer: I am not a financial advisor. This post reflects personal analysis and opinions only. Please do your own research before investing or trading.
0 · Reply
Trident1014
Trident1014 Mar. 4 at 3:44 PM
$AVTX Ph2 results next month
2 · Reply
Trapjaw
Trapjaw Mar. 4 at 3:44 PM
$AVTX strong vol ume 300 k first
0 · Reply
Trapjaw
Trapjaw Mar. 4 at 3:43 PM
$AVTX setup looks like yesterday
0 · Reply
Trapjaw
Trapjaw Mar. 4 at 1:22 PM
$AVTX
0 · Reply
Trapjaw
Trapjaw Mar. 4 at 1:17 PM
$AVTX
0 · Reply
DragonAlgo
DragonAlgo Mar. 4 at 5:54 AM
🐉 $AVTX CALL — DragonAlgo® Signal Contract: AVTX CALL Expiry: 2026-03-20 | Strike: $17.50 | Type: CALL Option Plan (premium): Entry: $1.80 Stop: $1.30 TP1: $2.34 TP2: $3.06 TP3: $4.32 🔗 https://dragonalgo.com
0 · Reply
Achandler787
Achandler787 Mar. 4 at 2:58 AM
$AVTX lots of catalysts coming
0 · Reply
Trapjaw
Trapjaw Mar. 3 at 9:00 PM
$AVTX
0 · Reply
Trapjaw
Trapjaw Mar. 3 at 7:58 PM
$AVTX 20,72 52 w high 🙏 ne high this month
0 · Reply
Trapjaw
Trapjaw Mar. 3 at 6:44 PM
$AVTX https://news.finvera.ai/quote/XNAS-AVTX?article=td-cowen-annual-healthcare-conference-avala-therapeutics
0 · Reply